The Fluoride Reversal: FDA, RFK Jr., and the Reckoning with Chemical Childhood

Why the removal of unapproved pediatric fluoride drugs is just the beginning.

In a move that quietly signals the beginning of a major regulatory realignment, the U.S. Food and Drug Administration announced on May 13, 2025, its intent to remove concentrated ingestible fluoride prescription drugs for children from the market. The decision, initiated under the direction of Health and Human Services Secretary Robert F. Kennedy Jr., marks a decisive turn against decades of inertia in public health policy. Though not accompanied by fanfare, this reversal is far from trivial. It lays bare a troubling fact: for over half a century, children across the United States have been prescribed fluoride tablets, drops, and lozenges—none of which were ever approved by the FDA.

These products were originally intended to compensate for low fluoride levels in drinking water, especially in non-fluoridated areas. Yet, somehow, they bypassed formal approval. There were no randomized controlled trials proving safety or efficacy, no systematic pharmacovigilance, and no rigorous toxicological evaluations. They were simply used—first cautiously, then routinely, and eventually dogmatically—becoming part of the standard pediatric toolkit.

The FDA’s new action plan sets a public comment period ending October 31, 2025, after which appropriate regulatory steps will follow. The agency’s rationale is straightforward: the products lack approved drug status and have not met the standards of modern safety and effectiveness evaluation. But behind the legal language lies a more profound reckoning—one that involves mounting concerns about fluoride’s role in altering neurodevelopment, gut ecology, and endocrine function during the most sensitive stages of human development.

Scientific challenges to systemic fluoride have accumulated over the past two decades. Longitudinal studies in populations with varying fluoride exposures have suggested consistent patterns: elevated fluoride levels during pregnancy or early childhood are associated with lower cognitive scores later in life. Research teams led by Bashash and Till—publishing in Environmental Health Perspectives and JAMA Pediatrics, respectively—have drawn attention to this signal. Though debated, these findings were strong enough for the National Toxicology Program (NTP) to issue a draft report in 2022 concluding that high levels of fluoride exposure are “presumed to be a cognitive neurodevelopmental hazard to humans.”

Beyond the brain, the fluoride question touches the gut. Emerging evidence indicates that systemic fluoride may alter the diversity and balance of the gut microbiome, which in turn influences immunity, metabolism, and brain development. Children are not simply miniature adults; their systems are under construction, and the long-term implications of repeated low-dose chemical exposures are still being discovered—often too late.

What makes this more damning is the shaky rationale for ingestible fluoride in the first place. The original theory—that systemic fluoride strengthens developing enamel before teeth erupt—has been increasingly challenged. Topical fluoride from toothpaste and varnishes appears to deliver the benefits with far less systemic risk. Even the Cochrane Collaboration, known for its rigorous meta-analyses, has expressed doubts about the value of fluoride supplements, noting limited and low-quality evidence supporting their effectiveness in reducing dental caries.

The fluoride saga illustrates how assumptions ossify into medical practice. Somewhere along the way, fluoride's reputation as a harmless cavity-fighter became unassailable, bolstered by public health authorities and dental associations eager to defend past decisions. Critics were marginalized. Dissent was branded as conspiracy. And meanwhile, parents continued administering fluoride tablets to their children, unaware that the FDA had never officially sanctioned their use.

But the Kennedy-era HHS is not playing by the old rules. RFK Jr.’s philosophy—articulated repeatedly throughout his career—is to err on the side of safety, especially when the subjects are children and the science is unsettled. His critics call him alarmist. His supporters call him courageous. Either way, the fluoride reversal is a statement: no chemical intervention should remain above scrutiny, no matter how entrenched or politically sacred.

Predictably, pushback has arrived. The American Dental Association and other stakeholders have raised concerns, warning that fluoride removal could increase childhood cavities. They cite historical reductions in caries rates as proof of fluoride’s benefit. But such correlations—often drawn without adjusting for confounding factors like diet, hygiene, or improved access to dental care—can no longer substitute for actual, mechanistic safety and efficacy data. The era of “because we’ve always done it that way” is being challenged, and for good reason.

Fluoride may just be the beginning. If fluoride was permitted without approval and stayed there for decades, what else in pediatric medicine fits that mold? Are there other legacy products or interventions resting on outdated assumptions, never subjected to modern safety science? Already, some are calling for an audit of pediatric practices—from overprescribed antibiotics to vitamin K analogs to vaccine combinations never tested together in placebo-controlled studies.

Parents, understandably, are left wondering what to do. Should they stop giving fluoride tablets to their children? The answer, based on current evidence and the FDA’s action, is yes—especially since the products are being targeted for removal precisely because they were never formally reviewed. Topical fluoride remains available for those who choose to use it, and pediatric dental hygiene does not depend on systemic exposure. Fluoride toothpaste, brushing habits, and sugar moderation still form the foundation of modern cavity prevention.

The deeper truth is this: fluoride was not simply a public health measure. It was a story—a story about science, trust, and government stewardship. That story is now being rewritten. The FDA’s move reflects a broader demand for accountability, transparency, and humility in the face of new evidence. Popular Rationalism has long advocated for the principle that science must never be final—it must remain open to correction, especially when lives and developing minds are at stake.

As the fluoride reversal unfolds, it signals a profound shift in public health philosophy. From one-size-fits-all mandates and chemical optimism, we may now be entering an era of cautious reappraisal. The age of blind trust is ending. And the age of evidence-based, child-centered precaution may—finally—be dawning.